A Phase 1 interventional study of KU-0059436 (AZD2281)(PARP inhibitor) and Gemcitabine in Pancreatic Neoplasms, sponsored by AstraZeneca. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-20.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing olaparib in Pancreatic Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. olaparib · Pancreatic Neoplasms.
Among the 14 studies testing olaparib in Pancreatic Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2007, is one of 5 in phase 1, and was the 1st registered.
3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →4 of the 14 studies testing olaparib in Pancreatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria di Modena · Sites in Italy
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Israel, Puerto Rico
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Herlev Hospital · Sites in Denmark
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 30 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
19 studies in Pancreatic Neoplasms by AstraZeneca: 3 open now, 5 under way, none of them phase 3. Of 14 finished, 4 (29%) have results posted.
Among the 19 studies in Pancreatic Neoplasms by AstraZeneca, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2007, is one of 5 in phase 1, and was the 4th registered.
AstraZeneca’s Pancreatic Neoplasms studies by the year they started, since 2002.
3 of the studies testing olaparib in Pancreatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05093231Cambridge University Hospitals NHS Foundation TrustPembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | 2026-11-30 |
| NCT04005690OHSU Knight Cancer InstituteTargeted Pathway Inhibition in Patients With Pancreatic Cancer | 2027-06-01 |
| NCT04858334National Cancer Institute (NCI)APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing olaparib in Pancreatic Neoplasms, from their registry updates:
Among AstraZeneca’s 19 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemcitabine + KU-0059436
Drug: KU-0059436 (AZD2281)(PARP inhibitor) · Drug: Gemcitabine
oral
Also known as: Olaparib
intravenous injection
Also known as: Gemzar®, Gemcitabine HCL
To establish the maximum tolerated dose (MTD) or a tolerable and effective dose of KU 0059436 in combination with gemcitabine
Time frame: assessed at each visit
To identify the dose-limiting toxicity of the combination therapy
Time frame: assessed at each visit
The record gives a start of Aug 2007, a primary completion of Oct 2011 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib